Lupron

Phase 3Small molecule

Lupron is one of 52 small molecule programs targeting Allogeneic Hematopoietic Stem Cell Transplantation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruiting

Prostate CancerCompleted

Allogeneic Hematopoietic Stem Cell TransplantationPhase 2

Active, not recruiting

Prostate CancerPhase 3

Completed

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

Radium-223

Bayer

Phase 3

6 4

AAA817

Novartis

Phase 3

1 5

Lupron

Radiation Therapy Oncology Group

Phase 3

6 6

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 7

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849

Q2 2031

Phase 2Recruiting

Prostate Cancer

NCT07027124

Clinical

Trials by Indication[1]

Prostate Cancer6 trials

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Terminated·—·Phase 3·NCT00243646·6 enrolled

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03572387·14 enrolled

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Terminated·PPharmatech·Phase 4·NCT02749825·41 enrolled

Show 3 more trials

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07027124·40 enrolled

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00002597·2,028 enrolled

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04331717

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01746849·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Lupron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lupron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lupron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radiation Therapy Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Radiation Therapy Oncology Group

Lupron

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2031

Trials by Indication[1]

Prostate Cancer6 trials

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News